Biocon Q4 FY25 Earnings Call Transcript Filed

Management guided margin improvementManagement guided margin pressureOrder pipeline disclosedCFO laid out a debt-reduction roadmapInvestor Communications View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹337.75

prior close

₹342.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.9%-0.5% vs market

Pharmaceuticals peers, median of 150sector+0.2%+0.2% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Midcap 150 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.4

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3+0.9-0.5+0.2+0.2

Next day

+1.2+1.0+0.2+1.1+0.1

-1.4-0.6-0.8+0.2-1.6

+0.8+0.2+0.6+1.0-0.2

-1.3-0.1-1.1+1.2-2.5

-2.0+0.4-2.4+0.7-2.7

-0.8+1.2-2.0+1.4-2.2

15d

-2.4+4.4-6.8+0.8-3.2

+5.7+3.9+1.8+2.1+3.6

+16.9+5.8+11.1+3.8+13.1

+7.7+2.3+5.4-1.0+8.7

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon reported Q4 FY25 revenue of Rs 4,417 crores, up 15 percent year on year on like-for-like basis, with core EBITDA of Rs 1,363 crores at 31 percent margin. Full year FY25 revenue was Rs 15,262 crores, core EBITDA Rs 4,264 crores at 28 percent margin, and reported net profit Rs 1,013 crores. Generics surged 46 percent YoY led by Lenalidomide. Biosimilars grew 9 percent. Key launches include Yesintek (Ustekinumab biosimilar) in US, Liraglutide in UK, and settlement for Aflibercept with US launch in H2 2026. Company plans Rs 4,500 crore fundraise via QIP and private placement, and board committee is studying possible merger of Biocon Ltd with Biocon Biologics.

Likely market impact

Strong quarter with broad based growth, major biosimilar launches ahead and potential merger evaluation could be positive for long term value.